Cell Therapy Investment Firms

RaiseHunt lists 42 Cell Therapy investment firms.

All 42 list at least one portfolio company, 328 known investments between them.

140 people working at them have a profile here, each with their role at the firm and whether an email address is on file.

The largest concentrations are in San Francisco, New York and Tokyo.

Most list Series B and Seed among their stages.

Every firm page shows whether an email address is on file, and the named contacts at that firm. The addresses themselves, along with AI matching and outreach, are in the RaiseHunt app.

Yes. The directory and every firm page are free to read. Matching your own startup against them requires an account.

No. A focus area is a signal of interest, not a restriction. Firms usually list several, and the useful question is whether the existing portfolio looks like the kind of company you are building.

Often, though not far outside. Sector tags describe where a firm concentrates rather than a rule it follows, and companies that sit between two categories get funded all the time. The stronger signal is whether the firm has backed a business with a similar shape, whatever label it carried.

Far more than feels comfortable. Response rates on cold outreach are low even when the fit is good, so a short list of perfect names tends to stall. Build a long list, sort it by how well each firm matches what you are building, and work down it in batches rather than sending everything at once.

A short deck, a one-paragraph description of what you do and who it is for, and a clear number for how much you are raising. Partners read the first two lines before they decide whether to open the deck, so those lines matter more than the rest of the document.

It helps, mostly because it moves your email out of a crowded inbox. It is not a requirement. A cold message that shows you understand what the firm has already backed, and why your company fits that pattern, gets read more often than a vague introduction from a distant contact.

Usually by a group rather than by the person you first spoke to. One partner sponsors the deal internally and takes it to the rest, which is why the process runs longer than an angel conversation and why a single enthusiastic meeting is not yet a commitment.